Valued at a market cap of $12.6 billion, Alexandria Real Estate Equities, Inc. (ARE) is a life science REIT headquartered in Pasadena, California. It owns, operates, and develops collaborative megacampus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. It is expected to announce its fiscal Q2 earnings for 2025 after the market closes on Monday, Jul. 21.

Prior to this event, analysts project this life science REIT to report an FFO of $2.30 per share, down 2.5% from $2.36 per share in the year-ago quarter. The company has met or exceeded Wall Street’s FFO estimates in three of the last four quarters, while missing on another occasion. Its FFO of $2.30 per share in the previous quarter outpaced the consensus estimates by a slight margin. 

For the full year, analysts expect ARE to report FFO of $9.21 per share, down 2.8% from $9.47 per share in fiscal 2024. Furthermore, its FFO per share is expected to decline marginally year over year to $9.16 in fiscal 2026.

ARE has declined 37.9% over the past 52 weeks, considerably lagging behind both the S&P 500 Index's ($SPX) 13.6% rise and the Real Estate Select Sector SPDR Fund’s (XLRE) 7.8% return over the same time frame.

On Apr. 28, ARE delivered better-than-expected Q1 results, yet its shares plunged 5.7% in the following trading session. The company’s revenue declined 1.4% year-over-year to $758.2 million due to lower income from rentals. However, the top-line figure outpaced the consensus estimates by 4.8%. Moreover, its adjusted FFO of $2.30 per share fell 2.1% from the year-ago quarter but marginally topped the analyst estimates.

Wall Street analysts are moderately optimistic about ARE’s stock, with a "Moderate Buy" rating overall. Among 13 analysts covering the stock, four recommend "Strong Buy," and nine indicate “Hold.” The mean price target for ARE is $97.31, which indicates a 34% potential upside from the current levels.